Benzinga · Oct 9, 2026
Raymond James Finl (NYSE:RJF) has outperformed the market over the past 15 years by 2.36% on an annualized basis producing an average annual return of 15.62%. Currently, Raymond James Finl has a market capitalization of
Yahoo · Oct 8, 2026
Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm’s Analyst Current Favorites list features biotechnology companies positioned for potential catalysts in 2025 and 2026.
Benzinga · Oct 9, 2026
Morgan Stanley analyst Michael Cyprys maintains Raymond James Finl (NYSE:RJF) with a Equal-Weight and lowers the price target from $174 to $171.
Yahoo · Oct 8, 2026
HSIIX, EISIX and UMBHX offer diversified active strategies, strong recent returns and low expense ratios for investors.
Yahoo · Oct 8, 2026
The advisors, who operated as a unified Raymond James branch since 2022, will keep the firm as their primary custodian while joining Dallas-based RIA platform Ascentis.